<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药融投资 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-16T16:31:41+08:00</updated>
  <subtitle>医药行业</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>大卖25亿美元GLP-1 ： Semaglutide获治疗NASH突破性疗法资格</title>
    <updated>2020-11-16T13:40:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/aq_aJs01cmj3jZi__iRQLw</id>
    <link href="https://mp.weixin.qq.com/s/aq_aJs01cmj3jZi__iRQLw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国新药研发烧钱之最：百济神州拟科创板IPO</title>
    <updated>2020-11-16T13:40:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/klYLwGKv1eOH_cMQrjjvzg</id>
    <link href="https://mp.weixin.qq.com/s/klYLwGKv1eOH_cMQrjjvzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>微芯生物最新调研：在研多进展，未来可期</title>
    <updated>2020-11-10T16:44:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/rK1klcQkqw2Iu8x-RYGfuA</id>
    <link href="https://mp.weixin.qq.com/s/rK1klcQkqw2Iu8x-RYGfuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田：炎性肠病重磅Vedolizumab上半年大卖20亿美元；国内开售</title>
    <updated>2020-11-10T16:44:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/mVEWhIQDXbO3Yx4VhHfYmw</id>
    <link href="https://mp.weixin.qq.com/s/mVEWhIQDXbO3Yx4VhHfYmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>大卖25亿美元GLP-1 ： Semaglutide获治疗NASH突破性疗法资格</title>
    <updated>2020-11-10T16:37:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/ak7Q7dBh9TTdFxNQL0Lt9Q</id>
    <link href="https://mp.weixin.qq.com/s/ak7Q7dBh9TTdFxNQL0Lt9Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>BMS原创氘代TYK2新药，3期银屑病临床击败阿普斯特</title>
    <updated>2020-11-10T16:37:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/q7GKPly081YNWNFZ0iiWTw</id>
    <link href="https://mp.weixin.qq.com/s/q7GKPly081YNWNFZ0iiWTw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内在研火热：标配BCL-2+BTK；礼来重金引进复创新药！</title>
    <updated>2020-11-05T15:23:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/WE3ObSnajokRIhUmk0PwMw</id>
    <link href="https://mp.weixin.qq.com/s/WE3ObSnajokRIhUmk0PwMw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>超低调：新和成控股又一力作，福元医药拟科创板IPO</title>
    <updated>2020-11-05T15:23:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/fV_r3nYR43LxtcCgK_m-5A</id>
    <link href="https://mp.weixin.qq.com/s/fV_r3nYR43LxtcCgK_m-5A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>干眼症市场火热 | 新药EYSUVIS获批，股票却大跌</title>
    <updated>2020-11-03T11:21:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/WnaqiR4Bm3bZLGTZmPCnmg</id>
    <link href="https://mp.weixin.qq.com/s/WnaqiR4Bm3bZLGTZmPCnmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恩格列净：在华递交心衰适应症NDA；化合物专利被无效</title>
    <updated>2020-11-03T11:21:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/dJQ6oZDyQibHfODvMs7bXg</id>
    <link href="https://mp.weixin.qq.com/s/dJQ6oZDyQibHfODvMs7bXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>多肽药物的江湖 | 创仿药/API/CDMO齐发力</title>
    <updated>2020-11-02T13:13:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/S5RjfAILgOsbUJzVTEMKKg</id>
    <link href="https://mp.weixin.qq.com/s/S5RjfAILgOsbUJzVTEMKKg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>道尔生物完成近亿元A+轮融资，推进多特异新药研发</title>
    <updated>2020-11-02T13:13:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/XfnMSsFNAmqKPzDErPXMpQ</id>
    <link href="https://mp.weixin.qq.com/s/XfnMSsFNAmqKPzDErPXMpQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新型临床CRO，太美医疗科创板辅导上市！</title>
    <updated>2020-11-02T13:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/j-iBEz11l9yWCYOepuXRbg</id>
    <link href="https://mp.weixin.qq.com/s/j-iBEz11l9yWCYOepuXRbg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融圈CEO+BD+VC联盟线下活动,成都站议程曝光</title>
    <updated>2020-11-02T13:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/HOKCxK573rzqqcu_UA-e5A</id>
    <link href="https://mp.weixin.qq.com/s/HOKCxK573rzqqcu_UA-e5A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融圈CEO+BD+VC联盟线下活动,成都站议程曝光</title>
    <updated>2020-10-30T09:32:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/avGqeSNITOjGmITvK7niaQ</id>
    <link href="https://mp.weixin.qq.com/s/avGqeSNITOjGmITvK7niaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>普克鲁胺治疗COVID-19的临床试验完成381例受试者入组</title>
    <updated>2020-10-30T09:32:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/VJBrJO0-2RT6fUuG_XN37w</id>
    <link href="https://mp.weixin.qq.com/s/VJBrJO0-2RT6fUuG_XN37w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺华：CAR-T疗法中国正式入组患者，未来可期</title>
    <updated>2020-10-30T09:23:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/fZ1c7Mp1KBfemzMuCaNCug</id>
    <link href="https://mp.weixin.qq.com/s/fZ1c7Mp1KBfemzMuCaNCug" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>KRAS再传利好：Mirati在研新药1/2期ORR/DCR数据积极</title>
    <updated>2020-10-30T09:23:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/STG2tOOGZRZh8hXOkJ9_TA</id>
    <link href="https://mp.weixin.qq.com/s/STG2tOOGZRZh8hXOkJ9_TA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Gossamer：2期FIC哮喘新药临床失败，公司市值大减</title>
    <updated>2020-10-29T17:08:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/uIJK_abhCN7vfdjZNi5mQA</id>
    <link href="https://mp.weixin.qq.com/s/uIJK_abhCN7vfdjZNi5mQA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>API中间体项目立项思考框架</title>
    <updated>2020-10-29T17:08:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/U8ckXm_JDidscGBJ-cnoaQ</id>
    <link href="https://mp.weixin.qq.com/s/U8ckXm_JDidscGBJ-cnoaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>